Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 79

1.

Identification of a coumarin-based antihistamine-like small molecule as an anti-filoviral entry inhibitor.

Cheng H, Schafer A, Soloveva V, Gharaibeh D, Kenny T, Retterer C, Zamani R, Bavari S, Peet NP, Rong L.

Antiviral Res. 2017 Sep;145:24-32. doi: 10.1016/j.antiviral.2017.06.015. Epub 2017 Jun 20.

2.

DNA Targeting as a Likely Mechanism Underlying the Antibacterial Activity of Synthetic Bis-Indole Antibiotics.

Opperman TJ, Kwasny SM, Li JB, Lewis MA, Aiello D, Williams JD, Peet NP, Moir DT, Bowlin TL, Long EC.

Antimicrob Agents Chemother. 2016 Nov 21;60(12):7067-7076. Print 2016 Dec.

3.

Synthesis and antifungal evaluation of head-to-head and head-to-tail bisamidine compounds.

Nguyen ST, Kwasny SM, Ding X, Williams JD, Peet NP, Bowlin TL, Opperman TJ.

Bioorg Med Chem. 2015 Sep 1;23(17):5789-98. doi: 10.1016/j.bmc.2015.07.006. Epub 2015 Jul 14.

4.

Diels-Alder reactions of five-membered heterocycles containing one heteroatom.

Ding X, Nguyen ST, Williams JD, Peet NP.

Tetrahedron Lett. 2014 Dec 17;55(51):7002-7006.

5.

Structure-activity relationships of a novel pyranopyridine series of Gram-negative bacterial efflux pump inhibitors.

Nguyen ST, Kwasny SM, Ding X, Cardinale SC, McCarthy CT, Kim HS, Nikaido H, Peet NP, Williams JD, Bowlin TL, Opperman TJ.

Bioorg Med Chem. 2015 May 1;23(9):2024-34. doi: 10.1016/j.bmc.2015.03.016. Epub 2015 Mar 13.

6.

Synthesis and structure-activity relationships of novel phenoxyacetamide inhibitors of the Pseudomonas aeruginosa type III secretion system (T3SS).

Williams JD, Torhan MC, Neelagiri VR, Brown C, Bowlin NO, Di M, McCarthy CT, Aiello D, Peet NP, Bowlin TL, Moir DT.

Bioorg Med Chem. 2015 Mar 1;23(5):1027-43. doi: 10.1016/j.bmc.2015.01.011. Epub 2015 Jan 13.

7.

Synthesis and antibacterial evaluation of new, unsymmetrical triaryl bisamidine compounds.

Nguyen ST, Williams JD, Butler MM, Ding X, Mills DM, Tashjian TF, Panchal RG, Weir SK, Moon C, Kim HO, Marsden JA, Peet NP, Bowlin TL.

Bioorg Med Chem Lett. 2014 Aug 1;24(15):3366-72. doi: 10.1016/j.bmcl.2014.05.094. Epub 2014 Jun 12.

8.

Mutations in the Pseudomonas aeruginosa needle protein gene pscF confer resistance to phenoxyacetamide inhibitors of the type III secretion system.

Bowlin NO, Williams JD, Knoten CA, Torhan MC, Tashjian TF, Li B, Aiello D, Mecsas J, Hauser AR, Peet NP, Bowlin TL, Moir DT.

Antimicrob Agents Chemother. 2014;58(4):2211-20. doi: 10.1128/AAC.02795-13. Epub 2014 Jan 27.

9.

Small molecule inhibitors of anthrax lethal factor toxin.

Williams JD, Khan AR, Cardinale SC, Butler MM, Bowlin TL, Peet NP.

Bioorg Med Chem. 2014 Jan 1;22(1):419-34. doi: 10.1016/j.bmc.2013.11.009. Epub 2013 Nov 13.

10.

Syntheses of Benzo[b]furan-6-carbonitrile and 6-Cyanobenzo[b]furan-2-boronic Acid Pinacol Ester.

Williams JD, Ding X, Nguyen S, Vines KK, Peet NP.

Synth Commun. 2013;43(14). doi: 10.1080/00397911.2012.684086.

11.

Characterization of a novel pyranopyridine inhibitor of the AcrAB efflux pump of Escherichia coli.

Opperman TJ, Kwasny SM, Kim HS, Nguyen ST, Houseweart C, D'Souza S, Walker GC, Peet NP, Nikaido H, Bowlin TL.

Antimicrob Agents Chemother. 2014;58(2):722-33. doi: 10.1128/AAC.01866-13. Epub 2013 Nov 18.

12.

Potent and broad-spectrum antibacterial activity of indole-based bisamidine antibiotics: synthesis and SAR of novel analogs of MBX 1066 and MBX 1090.

Williams JD, Nguyen ST, Gu S, Ding X, Butler MM, Tashjian TF, Opperman TJ, Panchal RG, Bavari S, Peet NP, Moir DT, Bowlin TL.

Bioorg Med Chem. 2013 Dec 15;21(24):7790-806. doi: 10.1016/j.bmc.2013.10.014. Epub 2013 Oct 25.

13.

New small molecule entry inhibitors targeting hemagglutinin-mediated influenza a virus fusion.

Basu A, Antanasijevic A, Wang M, Li B, Mills DM, Ames JA, Nash PJ, Williams JD, Peet NP, Moir DT, Prichard MN, Keith KA, Barnard DL, Caffrey M, Rong L, Bowlin TL.

J Virol. 2014 Feb;88(3):1447-60. doi: 10.1128/JVI.01225-13. Epub 2013 Nov 6.

14.

Human cytomegalovirus UL97 kinase is involved in the mechanism of action of methylenecyclopropane analogs with 6-ether and -thioether substitutions.

Komazin-Meredith G, Chou S, Prichard MN, Hartline CB, Cardinale SC, Comeau K, Williams JD, Khan AR, Peet NP, Bowlin TL.

Antimicrob Agents Chemother. 2014;58(1):274-8. doi: 10.1128/AAC.01726-13. Epub 2013 Oct 21.

15.

Human herpesvirus 6 U69 kinase phosphorylates the methylenecyclopropane nucleosides cyclopropavir, MBX 2168, and MBX 1616 to their monophosphates.

Komazin-Meredith G, Cardinale SC, Williams JD, Peet NP, Prichard MN, Bowlin TL.

Antimicrob Agents Chemother. 2013 Nov;57(11):5760-2. doi: 10.1128/AAC.00978-13. Epub 2013 Aug 26.

16.

Synthesis and antiviral activities of methylenecyclopropane analogs with 6-alkoxy and 6-alkylthio substitutions that exhibit broad-spectrum antiviral activity against human herpesviruses.

Prichard MN, Williams JD, Komazin-Meredith G, Khan AR, Price NB, Jefferson GM, Harden EA, Hartline CB, Peet NP, Bowlin TL.

Antimicrob Agents Chemother. 2013 Aug;57(8):3518-27. doi: 10.1128/AAC.00429-13. Epub 2013 May 13.

17.

Optimization of a novel potent and selective bacterial DNA helicase inhibitor scaffold from a high throughput screening hit.

Li B, Pai R, Aiello D, Di M, Barnes MH, Peet NP, Bowlin TL, Moir DT.

Bioorg Med Chem Lett. 2013 Jun 15;23(12):3481-6. doi: 10.1016/j.bmcl.2013.04.055. Epub 2013 Apr 30.

18.

Coumarin-based inhibitors of Bacillus anthracis and Staphylococcus aureus replicative DNA helicase: chemical optimization, biological evaluation, and antibacterial activities.

Li B, Pai R, Di M, Aiello D, Barnes MH, Butler MM, Tashjian TF, Peet NP, Bowlin TL, Moir DT.

J Med Chem. 2012 Dec 27;55(24):10896-908. doi: 10.1021/jm300922h. Epub 2012 Dec 11.

19.

Solute restriction reveals an essential role for clag3-associated channels in malaria parasite nutrient acquisition.

Pillai AD, Nguitragool W, Lyko B, Dolinta K, Butler MM, Nguyen ST, Peet NP, Bowlin TL, Desai SA.

Mol Pharmacol. 2012 Dec;82(6):1104-14. doi: 10.1124/mol.112.081224. Epub 2012 Sep 4.

20.

Synthesis and antiviral activity of certain second generation methylenecyclopropane nucleosides.

Williams JD, Khan AR, Harden EA, Hartline CB, Jefferson GM, Keith KA, Prichard MN, Zemlicka J, Peet NP, Bowlin TL.

Bioorg Med Chem. 2012 Jun 15;20(12):3710-8. doi: 10.1016/j.bmc.2012.04.049. Epub 2012 May 1.

21.

Time-dependent botulinum neurotoxin serotype A metalloprotease inhibitors.

Li B, Cardinale SC, Butler MM, Pai R, Nuss JE, Peet NP, Bavari S, Bowlin TL.

Bioorg Med Chem. 2011 Dec 15;19(24):7338-48. doi: 10.1016/j.bmc.2011.10.062. Epub 2011 Oct 26.

22.

Preparation and antibacterial evaluation of decarboxylated fluoroquinolones.

Nguyen ST, Ding X, Butler MM, Tashjian TF, Peet NP, Bowlin TL.

Bioorg Med Chem Lett. 2011 Oct 1;21(19):5961-3. doi: 10.1016/j.bmcl.2011.07.060. Epub 2011 Jul 29.

PMID:
21865042
23.

The challenge of developing robust drugs to overcome resistance.

Anderson AC, Pollastri MP, Schiffer CA, Peet NP.

Drug Discov Today. 2011 Sep;16(17-18):755-61. doi: 10.1016/j.drudis.2011.07.001. Epub 2011 Jul 19.

24.

Identification of a small-molecule entry inhibitor for filoviruses.

Basu A, Li B, Mills DM, Panchal RG, Cardinale SC, Butler MM, Peet NP, Majgier-Baranowska H, Williams JD, Patel I, Moir DT, Bavari S, Ray R, Farzan MR, Rong L, Bowlin TL.

J Virol. 2011 Apr;85(7):3106-19. doi: 10.1128/JVI.01456-10. Epub 2011 Jan 26.

25.

Small molecule inhibitors as countermeasures for botulinum neurotoxin intoxication.

Li B, Peet NP, Butler MM, Burnett JC, Moir DT, Bowlin TL.

Molecules. 2010 Dec 30;16(1):202-20. doi: 10.3390/molecules16010202. Review.

26.

Novel Benzimidazole Inhibitors of Botulinum Neurotoxin/A Display Enzyme and Cell-Based Potency.

Cardinale SC, Butler MM, Ruthel G, Nuss JE, Wanner LM, Li B, Pai R, Peet NP, Bavari S, Bowlin TL.

Botulinum J. 2011;2(1):16-29.

27.

Novel bis-indole agents active against multidrug-resistant Acinetobacter baumannii.

Jacobs MR, Bajaksouzian S, Good CE, Butler MM, Williams JD, Peet NP, Bowlin TL, Endimiani A, Bonomo RA.

Diagn Microbiol Infect Dis. 2011 Jan;69(1):114-6. doi: 10.1016/j.diagmicrobio.2010.08.014.

28.

Analysis of Botulinum Neurotoxin Serotype A Metalloprotease Inhibitors: Analogs of a Chemotype for Therapeutic Development in the Context of a Three-Zone Pharmacophore.

Burnett JC, Li B, Pai R, Cardinale SC, Butler MM, Peet NP, Moir D, Bavari S, Bowlin T.

Open Access Bioinformatics. 2010 Apr 1;2010(2):11-18.

29.

A concise, total synthesis and antibacterial evaluation of 2-hydroxy-1-(1H-indol-3-yl)-4-methylpentan-3-one.

Nguyen ST, Butler MM, Varady L, Peet NP, Bowlin TL.

Bioorg Med Chem Lett. 2010 Oct 1;20(19):5739-42. doi: 10.1016/j.bmcl.2010.08.003. Epub 2010 Aug 5.

PMID:
20805026
30.

Comparative in vitro activity profiles of novel bis-indole antibacterials against gram-positive and gram-negative clinical isolates.

Butler MM, Williams JD, Peet NP, Moir DT, Panchal RG, Bavari S, Shinabarger DL, Bowlin TL.

Antimicrob Agents Chemother. 2010 Sep;54(9):3974-7. doi: 10.1128/AAC.00484-10. Epub 2010 Jul 12.

31.

Drug resistance: a growing problem.

Peet NP.

Drug Discov Today. 2010 Aug;15(15-16):583-6. doi: 10.1016/j.drudis.2010.04.002. Epub 2010 Apr 29. No abstract available.

PMID:
20434584
32.

Efflux-mediated bis-indole resistance in Staphylococcus aureus reveals differential substrate specificities for MepA and MepR.

Opperman TJ, Williams JD, Houseweart C, Panchal RG, Bavari S, Peet NP, Moir DT, Bowlin TL.

Bioorg Med Chem. 2010 Mar 15;18(6):2123-2130. doi: 10.1016/j.bmc.2010.02.005. Epub 2010 Feb 10.

PMID:
20188576
33.

Discovery and characterization of inhibitors of Pseudomonas aeruginosa type III secretion.

Aiello D, Williams JD, Majgier-Baranowska H, Patel I, Peet NP, Huang J, Lory S, Bowlin TL, Moir DT.

Antimicrob Agents Chemother. 2010 May;54(5):1988-99. doi: 10.1128/AAC.01598-09. Epub 2010 Feb 22.

34.

Synthesis and biological evaluation of botulinum neurotoxin a protease inhibitors.

Li B, Pai R, Cardinale SC, Butler MM, Peet NP, Moir DT, Bavari S, Bowlin TL.

J Med Chem. 2010 Mar 11;53(5):2264-76. doi: 10.1021/jm901852f.

35.

A Survey of Solvents for the Conrad-Limpach Synthesis of 4-Hydroxyquinolones.

Brouet JC, Gu S, Peet NP, Williams JD.

Synth Commun. 2009 Jan 1;39(9):5193-5196.

36.

Aryl rhodanines specifically inhibit staphylococcal and enterococcal biofilm formation.

Opperman TJ, Kwasny SM, Williams JD, Khan AR, Peet NP, Moir DT, Bowlin TL.

Antimicrob Agents Chemother. 2009 Oct;53(10):4357-67. doi: 10.1128/AAC.00077-09. Epub 2009 Aug 3.

37.

Novel broad-spectrum bis-(imidazolinylindole) derivatives with potent antibacterial activities against antibiotic-resistant strains.

Panchal RG, Ulrich RL, Lane D, Butler MM, Houseweart C, Opperman T, Williams JD, Peet NP, Moir DT, Nguyen T, Gussio R, Bowlin T, Bavari S.

Antimicrob Agents Chemother. 2009 Oct;53(10):4283-91. doi: 10.1128/AAC.01709-08. Epub 2009 Jul 27.

38.

Biotechnology in India.

Peet NP.

Drug Discov Today. 2005 Sep 1;10(17):1137-9. No abstract available.

PMID:
16182204
39.

Genomics research: where are the drugs?

Peet NP.

IDrugs. 2000 Feb;3(2):131-2. No abstract available.

PMID:
16107918
40.

The multiple orthogonal tools approach to define molecular causation in the validation of druggable targets.

Hardy LW, Peet NP.

Drug Discov Today. 2004 Feb 1;9(3):117-26. Review.

PMID:
14960389
41.

Synthesis of 21,21-difluoro-3 beta-hydroxy-20-methylpregna-5,20-diene and 5,16,20-triene as potential inhibitors of steroid C17(20) lyase.

Weintraub PM, Holland AK, Gates CA, Moore WR, Resvick RJ, Bey P, Peet NP.

Bioorg Med Chem. 2003 Feb 6;11(3):427-31.

PMID:
12517438
42.

The utility of predictivity in drug discovery and use.

Peet NP.

Drug Discov Today. 2002 Feb 15;7(4):228-9. No abstract available.

PMID:
11839518
43.

Novel steroidal vinyl fluorides as inhibitors of steroid C17(20) lyase.

Burkhart JP, Weintraub PM, Gates CA, Resvick RJ, Vaz RJ, Friedrich D, Angelastro MR, Bey P, Peet NP.

Bioorg Med Chem. 2002 Apr;10(4):929-34.

PMID:
11836100
44.

The design and synthesis of purine inhibitors of CDK2. III.

Shum PW, Peet NP, Weintraub PM, Le TB, Zhao Z, Barbone F, Cashman B, Tsay J, Dwyer S, Loos PC, Powers EA, Kropp K, Wright PS, Bitonti A, Dumont J, Borcherding DR.

Nucleosides Nucleotides Nucleic Acids. 2001 Apr-Jul;20(4-7):1067-78.

PMID:
11562960
45.

Pharmacogenomics: challenges and opportunities.

Peet NP, Bey P.

Drug Discov Today. 2001 May 1;6(10):495-498. No abstract available.

PMID:
11369281
46.

Polystyrene-supported benzenesulfonyl azide: a diazo transfer reagent that is both efficient and safe.

Green GM, Peet NP, Metz WA.

J Org Chem. 2001 Apr 6;66(7):2509-11. No abstract available.

PMID:
11281799
47.

Crystal structure of human cyclin-dependent kinase 2 in complex with the adenine-derived inhibitor H717.

Dreyer MK, Borcherding DR, Dumont JA, Peet NP, Tsay JT, Wright PS, Bitonti AJ, Shen J, Kim SH.

J Med Chem. 2001 Feb 15;44(4):524-30.

PMID:
11170642
48.

Chemoinformatics: are we exploiting this new science?. 'We need to make chemoinformatics tools more accessible to the bench chemist.'

Hrib NJ, Peet NP.

Drug Discov Today. 2000 Nov 1;5(11):483-485. No abstract available.

PMID:
11084381
49.

Neurokinin receptor antagonists.

Leroy V, Mauser P, Gao Z, Peet NP.

Expert Opin Investig Drugs. 2000 Apr;9(4):735-46. Review.

PMID:
11060706
50.

The synthesis and biological activity of a highly selective adenosine A2a receptor agonist.

Borcherding DR, Lentz NL, Weintraub PM, Dudley MW, Secrest R, Kastner PR, Peet NP.

Nucleosides Nucleotides. 1999 Oct;18(10):2175-91.

PMID:
10616724

Supplemental Content

Support Center